The combination therapy can decrease Type 2 diabetes morbidity and mortality…

A gene called neurogenin3 proved critical to inducing cells in the liver to produce insulin on a continuing basis. They found that these “islet” cells came from a small population of adult stem cells usually found near the portal vein. Only a few are needed usually because.…

The amount of calcium your body absorbs might depend in part on the amount of dietary fiber you consume and new findings suggest that dietary fiber reduces ….

Among patients with incident Alzheimer’s disease, total and LDL cholesterol concentrations before diagnosis and a history of diabetes are associated with faster cognitive decline. Specifically, each 10-mg/dL increase in total cholesterol or LDL-C concentration was associated with an additional …

The study showed that “intensively lowering blood glucose to a target of 81 to 108 mg/dL does not benefit critically ill patients and may well increase their risk of…

Metformin beta-amyloid effect raises Alzheimer’s concerns. Diabetes is associated with increased risk for Alzheimer’s disease (AD), but a new study of metformin suggests that diabetes treatments might bear some of the blame.

More than half of Americans fear developing diabetes, but many continue the unhealthy behaviors that boost their odds of getting the blood sugar disease, a new survey shows.

A new review is coming out that is building on the suggested link between the consumption of fructose and increased food intake contributing to a high incidence of obesity and Type 2 diabetes.

When you don’t have diabetes and you start any activity, your body increases the release of glucose-raising hormones to prevent falls in your blood glucose levels. At the same time, your pancreas releases less insulin during exercise. But what about your patients who have diabetes? Sheri Colberg, Ph.D., FACSM, discusses …

Afresa is an ultra rapid-acting insulin. It is a drug-device combination product, consisting of Afresa Inhalation Powder pre-metered into single unit dose cartridges and the Afresa Inhaler as the delivery device for oral inhalation. Its pharmacokinetic profile make it different then Exubera, which was removed from the market.